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Abstract
To improve the anticancer activity of telmisartan, its structure has been modified by Zn(II) complexation giving
[Zn(Telm)2(H2O)2]·2H2O (ZnTelm). The cytotoxic effect was measured on the human lung cancer cells (A549) and on the lung
fibroblast cells (MRC-5). The complex markedly improved anticancer activity (IC50 75 μM) of telmisartan (IC50 125 μM) or
ZnSO4 (IC50 225 μM) and did not show toxicity on non-cancer cells, inducing oxidative stress with cellular ROS generation and
GSH/GSSG decrease. Apoptosis was the dominant form of cell death for the complex. The Bax/Bcl-XL ratio was significantly
increased as well as caspase-3 activation. Both the complex and the ligand bind to bovine serum albumin (BSA) and can be stored
and transported by the protein but the interaction with the complex is greater. Telmisartan binds BSA by hydrophobic interactions
while the interaction of ZnTelm occurs through van der Waals forces and hydrogen bonding. Therefore, it can be shown that the
coordination complex ZnTelm improved the anticancer activity of the antihypertensive drug telmisartan (IC50 75 μM and
125 μM, respectively) and the interaction with BSA.
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Introduction
Telmisartan, a member of the Angiotensin II receptor blockers
(ARBs), is an effective antihypertensive compound which has
stronger affinity to bind the AT1 receptor site [1]. Furthermore,
several reports have demonstrated that telmisartan has the capac-
ity to exert cytotoxic effects in human lung adenocarcinoma
A549 cell line [2] as well as apoptosis induction, ROS genera-
tion, and autophagy flux inhibition [3, 4]. Telmisartan (Fig. 1) is a
flexible ligand with four nitrogen atoms in the benzimidazole
groups and two oxygen atoms in the carboxylic acid group that
ensures diverse binding modes.
The essential trace element zinc is related to multiple
biological processes including catalytic, regulatory, and
structural. It also participates in reproduction, cell prolif-
eration, and systems of defense against ROS [5, 6].
Dietary deficiencies of zinc can increase oxidative injury
compromising DNA repair mechanisms, promoting DNA
damage [7, 8] and therefore they are associated to cancer.
Previous reports on the interaction of Zn(II) with
telmisartan showed two compounds a coordination Zn-Cu
complex, [Zn1.6Cu6.4Telm16], that was obtained by cation
exchange from [Cu8Telm16] [9] and a zinc salt of
telmisartan that has been synthesized in the form of the ionic
salt, Zn(Telm)2 [10]. The salt improved some physicochem-
ical and pharmaceutical properties of the drug but the spec-
troscopic characterization and the evaluation of its mecha-
nism of action in cancer cells were not reported. In the pres-
ent study, we have designed and characterized a coordina-
tion compound between Zn(II) and telmisartan and evaluat-
ed it as a potential anticancer compound against human lung
adenocarcinoma A549 cells and determined the mecha-
nisms of action and its selectivity against embryonic human
lung fibroblasts MRC-5 cell line. To ascertain the transport
and delivery in plasma, the interactions of the compounds
with BSAwere determined.
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Biopack (Argentina) and Rundu Pharma (Shangai, China)
supplied Zinc(II) chloride (97% purity) and telmisartan, re-
spectively. The reagents and solvents used were of analytical
grade. For the measurement of the infrared spectra (IR) of the
solids, a Bruker IFS 66 FTIR spectrophotometer in KBr pel-
lets in a range from 4000 to 400 nm was used. A Shimadzu
system (model TG-50) was used for the thermogravimetric
(TGA) analyses, at a heating rate of 10 °C min−1 and constant
oxygen flow of 50 mLmin−1. A Carlo Erba EA 1108 analyzer
was used for the determination of elemental analyses for C, H,
and N. Electronic and fluorescence spectra were recorded in a
Hewlett-Packard 8453 diode-array and a Shimadzu RF-6000
spectrophotometer, respectively. Zn content determination
was carried out by atomic absorption spectrometry. A
Bruker Ultrashield 600, 14.1 Tesla spectrometer was used
for 1H and 13C NMR measurements, working with 100%
DMSO-d6 solution (0.01 M concentrations) at 25 °C.
Tetramethylsilane was used as internal standard for calibrating
chemical shift δ.
Synthesis of [Zn(Telm)2(H2O)2]·2H2O
A 10-mL solution of telmisartan (0.2 mmol, 0.102 g), in 96%
ethanol at pH 7 (adjusted by the addition of aqueous solution
1 M NaOH), was stirred at 70 °C. Then, a solution of ZnCl2
(0.1 mmol, 0.013 g) in 5 mL of ethanol was added dropwise.
The resulting solution was left at ambient temperature, and
upon 24 h evaporation, a white powder was obtained. The
solid was filtered over a glass filter, washed with hot ethanol,
and air-dr ied. Elemental analys is (%): Calc for
C66H66N8O8Zn: C, 68.0; H, 5.6; N, 9.7; Zn, 5.7. Found: C,
67.8; H, 5.4; N, 9.5; Zn, 5.5. TGA measurements showed two
labile water molecules that were lost at 60 °C (% calc, 3.1; %
exp. 3.0). The next step at 226 °C (% calc, 3.1; % exp. 2.9)
was consistent with the loss of two coordinated water mole-
cules. UV-Vis (DMSO): 297 nm. Photoluminescence proper-
ties: λex 343 nm; λem: 381 nm (telm); λem 383 nm (ZnTelm).
1H NMR (600MHz, DMSO-d6) (δ ppm): 0.97(s, 3H), 1.79(s,
2H), 2.56 (s, 3H), 2.89(s, 3H), 3.35 (m, 8H), 3.70 (s, 3H),
5.44(s, 2H), 7.01–7.69 (m, 14H). 13C NMR (150 MHz,
DMSO-d6) (δ ppm): 14.27, 16.86, 21.24, 29.18, 32.06,
46.88, 111, 111.1, 119.1, 122.19, 122.98, 123.53, 126.66,
127.10, 128.58, 129, 129.13, 129.25, 129.97, 134.97,
135.11, 139.5, 141.46, 143.36, 154.81, 156, 173.87. FTIR:
C=O (CCOH in Tlm, 1696 cm−1) splits into νas(COO
−)
1592 cm−1 and νs(COO
−)1400 cm−1 in ZnTelm (monodentate
coordination).
Cell Culture Techniques
A549 cells (human lung carcinoma) andMRC-5 cells (embry-
onic human lung fibroblasts) were used for testing the anti-
cancer activities of the compounds. The cells were transferred
into 6- or 48-well plates (2 × 106 cells mL−1), and after 24 h,
they were grown to 85–90% confluency in Dulbecco’s mod-
ified Eagle’s medium (DMEM, Gibco/BRL) supplemented
with 10% fetal bovine serum (FBS, Internegocios SA).
Solutions of ZnSO4, telmisartan and ZnTelm dissolved in
2.5 μL DMSO plus 500 μL DMEM without FBS were added
to each well in order to obtain a final concentration between 0
and 100 μM.
Anticancer Activity
Cell Viability Assay, ROS Generation, GSH Levels,
and GSG/GSSG Ratio
After 24 h incubation with the compounds, the cytotoxicity
was tested by the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-di-
phenyltetrazolium bromide, Abcam, Cambridge, UK) assay.
Cells were incubated with 250 μL of the solution, followed by
3 h incubation. Then, DMSO was added into each well to
dissolve the purple formazan crystals. The optical density
was measured at 560 nm.
The intracellular ROS were detected using the H2DCFDA
probe (2,7-dichlorodihydrofluorescein diacetate). After 24 h
incubation with the complex, telmisartan and ZnSO4, A549
cells were incubated for 90 min with 10 μM H2DCFDA
(Merck, Darmstadt, Germany) at 37 °C in the dark.
Subsequently, the cells were collected and lysed in 0.1%
Triton X-100 solution (Biopack, Argentina). The intracellular
ROS were detected by spectrofluorometry (λexc = 485 nm and
λem = 520 nm).
The GSH levels and GSH/GSSG ratio were measured
with a spectrofluorometer using the modified Hissin and
Hilf’s method [11]. For GSSG measurements and to mask
GSH contents, 100 μL cellular aliquots were incubated
with 0.04 M of N-ethylmaleimide (NEM, after 24 h incu-
bation with the compounds), then NaOH (1.8 mL, 0.1 M,







Fig. 1 Structure of telmisartan
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a dd i t i o n o f 0 . 1% me t h a no l i c s o l u t i o n o f o -
phthaldialdehyde (OPT) was carried out. For GSH mea-
surements, 100 μL aliquots of lysed cells were mixed
with 1.8 mL of phosphate buffer (Na2HPO4 0.1 M-
EDTA 0.005 M, pH 8, ice-cold) and 100 μL of 0.1%
OPT were added. Fluorescence measurements were per-
formed at 420 nm (λexc = 350 nm). Protein content was
estimated using the Bradford technique [12]. Calibration
curves using GSH and GSSG as standard solutions
(Sigma-Aldrich) were used to calculate the microgram
GSH/milligram protein ratio. The ratio was expressed as
percentage of the control.
Apoptosis, Fluorescence Microscopy, and Western Blotting
Assay
The cellular and nuclear morphological alterations of the
A549 cells were confirmed by fluorescence microscopy
with acridine orange (AO) and ethidium bromide (EB)
staining procedure [13]. In 35-mm Petri dish, 2 ×
106 cells mL−1 were cultured and after 24 h incubation,
75 μM of ZnSO4, telmisartan, and ZnTelm were added.
For the negative control, 0.5% of DMSO and, for the
positive control, 1% of H2O2 were added. After 24 h,
the medium with the detached cells was collected, the
adherent cells were raised off with TrypLE express
(Gibco) and both liquids were centrifuged. The pellet
was suspended in 1 mg mL−1 AO/EB in PBS solution
for 10 min. The cell morphologies were analyzed under
an inverted fluorescence microscope Olympus CX-35.
The effects of ZnSO4, telmisartan, and ZnTelm on Bax,
Bcl-XL, and caspase-9 expression were observed by
Western blotting analysis. A549 cells were cultured with
75 μM (IC50 of the complex) concentration of the com-
pounds for 24 h. The cells were suspended in RIPA lysis
buffer (pH 7.4, 50 mM Tris, 2.5 mg mL−1 deoxycholic
acid, 10 μg mL−1 Nonidet-40, 150 mM NaCl, 1 mM
EGTA), containing the protease inhibitors cocktail:
0.95 μg mL−1 aprotinin, 2.5 μg mL−1 leupeptin, and
2.5 mM phenylmethylsulfonyl fluoride (pH 7.4). Then,
the isolated proteins were transferred to nitrocellulose
membranes at 50 V for 2 h. Membranes were blocked
followed by overnight incubation at 4 °C with the corre-
sponding primary antibody anti-β actin (1/750, Sigma-
Aldrich) to normalize the blottings, anti-Bax (1/750),
anti-Bcl-XL (1/1000), and Caspase-9 (1/750) (Santa
Cruz Biotechnology, CA, USA) and secondary antibody
(1:1000) (Jackson Immunoresearch Inc., USA) conjugated
to horseradish peroxidase in 5% skim milk for 1 h at 4 °C.
An Opti4CN kit (Bio-Rad, CA, USA) was used to detect
the bands of interest and they were analyzed using ImageJ
software. To express the results, the ratio (protein of in-
terest OD/β-actin OD) × 100 was determined.
BSA Interaction
Because the intrinsic fluorescence of telmisartan and ZnTelm
(360 and 368 nm, respectively) appeared in the same spectral
region of that of BSA, the quenching measurements were
performed at fixed concentrations of the ligand and complex
and variable BSA concentrations. BSA solutions were pre-
pared dissolving the albumin in Tris-HCl buffer (0.1 M,
pH 7.4) to attain final concentrations of 0, 2, 6, 10, 20, and
30 μM. Solutions of telmisartan and ZnTelm in DMSO were
added to the BSA solution at final concentrations of 10 μM
and incubated at 298 and 310 K for 1 h. The fluorescence
spectra were measured at λexc = 280 nm and λem = 290–
450 nm with spectral bandwidths of at 10 nm. The spectra
were deconvolved by the curve-fitting method with the
Levenberg–Marquardt algorithm. The OriginPro 9.1.0
(OriginLab Corporation, Northampton, USA) software was
used for the baseline corrections, normalization, curve-fitting
and calculations.
Statistical Analysis
All the data represent the mean ± standard error of the mean
(SEM) of results obtained from at least three independent
experiments, and each was performed by triplicate.
Statistical analysis was performed by one-way ANOVA test
followed by Fisher’s test using the OriginPro 9.1.0 (OriginLab
Corporation, Northampton, USA) software. p < 0.05 values
were considered statistically significant.
Results
Spectral Characterization
According to the elemental analysis of ZnTelm and the ther-
mal measurements , a L:M 2:1 stoichiometry for
[Zn(Telm)2(H2O)2].2H2O has been suggested. The assign-
ment of the FTIR vibration spectral bands of telmisartan and
its Zinc(II) complex (Table S1) was performed by comparison
with previous data of telmisartan and its copper complex [14].
The Δ(COO−) value for the complex (192 cm−1) indicated
that the carboxylate moiety binds to the metal center in a
monodentate mode. The reduction in the intensity of the spec-
tral modes related to the O–H group of the –COOH group
indicated the deprotonation and/or coordination of the ligand,
suggesting that telmisartan bound to the metal ion through the
carboxylate (COO−) group. Similar results have previously
been obtained for the telmisartan complexes of Y(III) and
Nd(III) [15]. The chemical shifts in the 1H-NMR spectrum
of the complex (Fig. S1) are similar to those of telmisartan
[16, 17] but showed the disappearance of the signal due to the
carboxylic acid proton, indicating, again the –COOH
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deprotonation during the complex formation. The broad sin-
glet at δ 3.35 ppm has been assigned to coordinated water. The
13C NMR spectral data for the Zn complex revealed that the –
COOH signal was shifted downfield upon complexation, due
to the bonding of the oxygen atom of the carboxylate group of
telmisartan with Zn(II). Therefore, the experimental results
using two spectroscopic techniques indicated that the Zn(II)
ion interacted with telmisartan trough the aromatic carboxyl-
ate of the ligand (Fig. 2).
Anticancer, Oxidative Stress, Apoptosis
The cytotoxicity of ZnSO4, telmisartan, ZnTelm, A549, and
MRC-5 cell line was investigated by the MTT assay. Results
were expressed as percent with respect to basal values.
Figure 3 a shows that ZnSO4 did not exert deleterious effects
on A549 cells while telmisartan only exerted significant tox-
icity at high concentrations (100 μM). The complex signifi-
cantly induced cell death on A549 cells in dose dependent
response (IC50 = 75 ± 8.1 μM). The data are consistent with
previous investigations on telmisartan that has shown to be
mildly toxic in A549 cell line by MTT assay after 24 h expo-
sure, with a ca. 40% reduction on cell viability at 50 μM [2,
18]. The MTT assay performed on the MRC-5 cells revealed
that at low doses of ZnSO4, the cell proliferation increased up
to 25 μM, and then the viability slowly decreases. Telmisartan
did not exert toxic behavior on the MRC-5 cells (Fig. 3b), like
the previous effects found for normal fibroblasts [18]. Cell
viability upon incubation of the complex in the MRC-5 cell
line resulted slightly affected suggesting that ZnTelm has the
ability to target selectively the A549 cancer cells.
To evaluate if the toxic mechanism of action occurs through
the induction of intracellular ROS production, A549 cells, incu-
batedwith different doses of ZnSO4, telmisartan, and ZnTelm for
24 h, were assessed using the oxidant-sensitive dye H2DCFDA.
The compounds have the potential to induce ROS production in
A549 cells in a concentration-dependent manner as shown in
Fig. 4a. These data agree with previous results: telmisartan trig-
gers ROS formation in leukemia cell lines [19] and ZnSO4 in
mammary adenocarcinoma [20]. From Fig.4a, it can be seen that
Fig. 2 Proposed structure for
ZnTelm
Concentration [ M]

























































Fig. 3 Viability of the A549 (a) andMRC-5 (b) cell lines with successive
additions of ZnSO4, telmisartan, and ZnTelm for 24 h. Each result (per-
formed in triplicate) represents the mean ± standard error of the mean
(SEM) of three independent experiments. Cell viability was calculated as
the percentage of live cells compared to the control (% basal).
*Statistically significant values between A549-treated cells and control
(p < 0.05). #Statistically significant values between ZnSO4, telmisartan
and ZnTelm at the same concentration (p < 0.05)
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in the treatment of ZnTelm at the IC50 dose (75μM), intracellular
ROS levels were significantly higher compared to the same con-
centration of telmisartan. These data suggest that the coordination
of Zn2+ with telmisartan generating a single molecule would
enhance the disruptive action on the cellular redox state.
Metal complexes can interfere in cellular redox chemistry in
several ways: directly through metal or ligand redox centers or
indirectly by binding to biomolecules involved in cellular redox
pathways [21]. At physiological pH value, the ligand is
deprotonated bearing a negative charge. In the complex, two
ligands neutralize their electrical charge with the Zn(II) ion and
facilitate the transport of the lipophilic complex through the cell
membrane by passive diffusion interacting non-covalently with
proteins or intercalating into the DNA molecule. Besides, metal
complexation confers more rigidity to the ligand favoring DNA
intercalation, so a positive synergic effect may occur.
To determine whether ROS increment could result in the nat-
ural antioxidant glutathione (GSH) depletion and cell death,
GSH levels have been measured. GSH, a tripeptide non-protein
thiol compound, acts as a defense system against oxidative stress
that oxidized to (GSSG). Therefore, GSH/GSSG ratio could be a
good signal of oxidative stress generation. The method devel-
oped by Hissin and Hilf [11] has been used to determine GSH
and GSSG levels. Treatment with telmisartan and ZnTelm
caused downregulation of GSH levels in a dose–response man-
ner; however, ZnTelm decreased the cellular GSH contents and
the GSH/GSSG ratio at lower concentrations than telmisartan
(Fig. 4b and c, respectively). This decline is concomitant with
ROS generation by both compounds hence it can be assumed
that free radicals production plays a key role in the toxic effects of
the commercial drug and the complex. On the other hand, it was
shown that the exposure to large concentrations of exogenous
zinc induces cytotoxicity in A549 cells (IC50 287.1 μM) having
low impact in the viability at 50 μM and 100 μM. However, at
these low concentrations, the indicators of oxidative stress are
increased [22].
To establish if apoptosis is the mechanism of target dell death
by ZnTelm, acridine orange/ethidium bromide double staining
assay was performed. AO penetrates the cells, and due to its
intercalation with DNA, green fluorescence emission in living
cells was observed. Furthermore, it acted as a weak base in active
acidic lysosomes exhibiting red fluorescence which can be ob-
served as red granules [23]. The red fluorescence emission of the
intercalating agent ethidium bromide occurred with altered (late
apoptotic or necrotic) cell membranes. Hence, four different cel-
lular stages could be distinguished with this technique: bright
green nuclei, live cells (control); orange irregular nuclei
displaying apoptotic bodies, early apoptotic cell; orange to red
nuclei with highly fragmented chromatin, late apoptotic cells;
and red fluorescence, necrotic cells. The treatment with 75 μM
ZnSO4 (IC50 of the complex) did not produce cellular alteration
(Fig. S2). Cells treated with 75 μM telmisartan induced ca. 39%
cellular death with 6% found to be early apoptosis, 17% late
apoptosis and 21% of necrosis (Fig. 5; Table S2). ZnTelm pro-
duced ca. 52% of cellular death, 30% of cells in early apoptosis,
21% late apoptosis, and 2% of necrosis. Moreover, ZnTelm gen-
erated red granules corresponding to lysosomes, which are in-
volved in the initiation of apoptosis [24]. Previous studies
showed that telmisartan mediates low frequencies of early and
late apoptotic events against renal cancer cells at large concen-
trations (100 and 200 μM) [25]. Granular apoptotic bodies,
membrane blebbing, and cell shrinkage, indicating apoptosis,
were observed in response to ZnTelm treatment in A549 cells
as themainmorphological changes. As awhole, our data suggest
that the main mechanism of A549 cell death produced by
ZnTelm treatment could be early apoptosis. In contrast, the treat-














































































Fig. 4 Effects of 0–100 μM ZnSO4, telmisartan, and ZnTelm on ROS
production (a), GSH level (b), and GSH/GSSG ratio (c) in A549 cell line.
Each result represents the mean ± standard error of the mean (SEM) of
three independent experiments and each was performed by triplicate.
*Statistically significant values between A549-treated cells and control
(p < 0.05). #Statistically significant values between ZnSO4, telmisartan,
and ZnTelm at the same concentration (p < 0.05)
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During apoptosis (programmed cell death), a group of in-
tracellular proteases, caspases, are responsible for a proteolyt-
ic degradation of a host of intracellular proteins into apoptotic
bodies. The protein expression of apoptosis regulators, includ-
ing Bax and caspase-3 (pro-apoptotics) and Bcl-XL
(antiapoptotic), was measured by Western blotting. The ex-
pression of caspase-3 and Bax upon incubation with ZnTelm
increased with respect to the control group, telmisartan, and
ZnSO4, while the expression of Bcl-XL decreased (Fig. 6), in
accord to the results obtained by AO/BE staining: ZnTelm
promotes apoptosis in A549 cells.
It can be concluded that the combination between
Zn(II) and telmisartan with proven anticancer properties
may cause synergetic effects to potentiate the anticancer
activity in the complex. The mechanism results from ox-
idative stress induced apoptotic signaling as a conse-
quence of an increase in ROS generation and depletion
in natural antioxidants.













Fig. 5 Plot of percentage of live
A549 cells and cell death stages.
Cell death stage was analyzed by
counting AO/BE–stained cells









































Fig. 6 a Western blotting of the
expression levels of Bax, Bcl-XL,
and Caspase 3 proteins in A549
cells incubated with 75 μM of
ZnSO4, telmisartan, and ZnTelm
(Internal control: β-Actin), in
three independent experiments. b
Densitometric quantification of
relative protein levels. c Bax/Bcl-
XL ratio. *Values statistically
significant between A549-treated
cells and control (p < 0.05).
#Values statistically significant
between telmisartan, ZnSO4, and





The major protein in plasma, albumin, is able to bind and
transport a wide diversity of compounds with high affinity
as a reversible process [26, 27]. The fluorescence measure-
ments for the determination of the interaction of some organic
molecules to proteins can give information on its mechanism,
binding constants, and binding sites.
The measurement of the fluorescence intensities before and
after the addition of different amounts of BSA to telmisartan
and ZnTelm allowed the determination of their interactions.
This procedure was chosen because at 280 nm (λex BSA), the
emission spectra for both telmisartan and ZnTelm were very
significant (due to the presence of biphenyl and benzimidazole
groups) [28] and the spectra overlapped with that of BSA.
Figure S3 shows the regular decrease of the intrinsic fluores-
cence of telmisartan and ZnTelm with successive BSA addi-
tions, indicating the interaction with the compounds. The
maximum emission wavelengths of telmisartan and ZnTelm
at pH 7.4 are located at 360 nm. The maximum fluorescence
emission of telmisartan-BSA (375 nm) and ZnTelm-BSA
(380 nm) shifted to the red (Fig. S3), suggesting an increase
of the hydrophilic microenvironment around the benzimid-
azole group.
Data analysis, at 298 K and 310 K, was performed with the
Stern-Volmer equation:
F0=F ¼ 1þ kqτ0 Q½  ¼ 1þ KSV Q½  ð1Þ
where F0 and F are the fluorescence intensities before and
after quencher addition, respectively, Kq is the bimolecular
quenching constant, [Q] is the concentration of the quencher,
τ0 is the half-life of the fluorophore without quencher, and Ksv
is the quenching constant of Stern-Volmer. The maximum (F)
and the initial (F0) fluorescence values of telmisartan and
ZnTelm were obtained from the wavelength of maximum
fluorescence shifts of the deconvolved spectra. Therefore,
from Eq. 1, Ksv can be determined from the linear regression
of the plot F0/F vs. albumin concentration (Fig. S4). Both
graphs show linearity for all tested BSA concentrations, indi-
cating that the quenching could be static or dynamic. The
calculated values of Ksv (Table 1) show that these constants de-
crease with the increment of the temperature, evidencing that the
possible mechanisms of interaction are static in both cases.
The equilibrium between free and bound small molecules
upon binding to some sites of the protein is described by the
Scatchard equation:
log F0−Fð Þ½  ¼ logKa þ nlog Q½  ð2Þ
that allow the calculation of the binding constant (Ka) and the
number of binding sites (n) (Fig. S5; Table 1). From this eval-
uation, only one binding site for the interaction of both
telmisartan and ZnTelm to BSA was determined. In general,
the value of Ka for the interaction compound-albumin must be
high enough to ensure the transport and distribution through-
out the body, but simultaneously, low enough to allow the
compound to be released to reach its goal. The optimal Ka
range is between 104 and 106 M−1 [29]. Therefore, our results
(Ka ca. 10
4 M−1) confirmed that the carrier BSA could bond
and transport the present compounds.
The type of interactions existing between the ligand and the
complex with BSA were evaluated from the thermodynamic
parameters (ΔH, ΔS, and ΔG). The enthalpy (ΔH) and the
entropy (ΔS) changes can be estimated using the van’t Hoff
eq. (3)
lnKa ¼ −ΔHo=RTð Þ þ ΔS0=R
  ð3Þ
where R is the gas constant. The free energy change, ΔGo,
was calculated from eq. (4):
ΔGo ¼ ΔHo−TΔSo ð4Þ
The negative sign for ΔG (Table 2) suggests that complex
formation with BSA is spontaneous. Different types of inter-
action could be involved in the process of protein association,
and they could be evaluated considering the magnitude of the
enthalpy and entropy changes. Positive changes of both pa-
rameters indicated hydrophobic interactions; negative values
indicated that Van der Waals forces and hydrogen bonding
bonds are acting between the compound and the protein and
ΔH < 0 andΔS > 0 are indicative for electrostatic interactions
[30]. Therefore, from Table 2, it can be seen that BSA-Telm
binds through hydrophobic interaction (ΔH > 0 and ΔS > 0)
probably due to the stacking generated by the aromatic rings
of BSA (tryptophan, phenylalanine, and tyrosine) and the ar-
omatic rings of the ligand. The stabilization of the bond
through hydrophobic interactions between telmisartan and
Table 1 Ksv: Stern-Volmer con-
stant,Kq: quenching rate constant,
andKa: binding constant, for BSA
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human serum albumin (HSA) has previously been reported
[31]. On the contrary, the negative values of ΔH and ΔS for
the ZnTelm-BSA complex are indications that van der Waals
forces and hydrogen bonding are acting in the binding
reaction.
Discussion
Metals ions, in particular, transition metals, offer a diversity of
properties when they bind to organic ligands. Cisplatin and
other platinum derivatives are coordination complexes used
successfully as anticancer drugs but display serious side ef-
fects, general toxicity, and drug resistance. As a consequence,
new coordination compounds with promising activities on the
therapy for carcinogenic diseases have been designed. It is
known that a deficiency in the homeostasis of zincmetabolism
can cause the progression of oncogenic processes [32] and
that telmisartan is an effective drug in lowering blood pressure
with a demonstrated inhibitory effect on lung cancer cell pro-
liferation [3]. Therefore, we hypothesized that a coordination
compound between Zn(II) and this medication could improve
the anticancer activity of the commercial antihypertensive
drug. The ZnTelm complex has been successfully synthe-
sized, and the characterization has been performed by means
of spectroscopic techniques.
The anticancer effects of telmisartan in A549 cells have
previously been reported [2, 18]. We found that ZnTelm
showed a significantly high potency with a lower value of
IC50 and no cytotoxic effects against MRC-5 cell line were
observed. The treatment with Zn(II) ions up to 100 μMdid not
decrease the cell viability in agreement with other reports [33,
34]. These findings clearly indicated that the structural modi-
fication of telmisartan by Zn(II) complexation ameliorated the
anticancer effect in the tested human lung cancer cells with
selectivity. The cellular damage induced by oxidative stress is
an essential factor for the design of novel cancer-targeting
drugs. Telmisartan stimulated cellular ROS production [4],
and ZnTelm triggered higher levels of ROS. Increased ROS
generation together with decreased GSH (and GSH/GSSG)
levels are important contributions on the mechanism of cell
death by oxidative stress. The couple GSH and GSH/GSSG
ratio for the complex showed a higher depletion in lung cancer
cells. Moreover, the induction of apoptosis can be activated by
two mechanisms: the death receptor signaling that is indica-
tive of the extrinsic pathway andmitochondrial alterations that
describe the intrinsic pathway. The intrinsic pathway followed
by caspase activation is controlled by the Bcl-2 (pro- and
antiapoptotic) protein family [35]. The results revealed that
ZnTelm had a greater effect in the early phase of apoptosis
while telmisartan showed necrotic cells at the same concen-
tration. To investigate the basic molecular mechanisms of ap-
optosis induced by ZnTelm in A549 cells, the expression
levels of the pro-apoptotic Bax and antiapoptotic Bcl-XL pro-
teins as well as the death executor caspase-3 were determined.
Telmisartan slightly increased the Bax expression and
caspase-3 activation as shown in other reports [36, 37].
However, ZnTelm treatment showed a strong increment of
both proteins. Regarding Bcl-XL expression, telmisartan
dropped off the level while in ZnTelm group, a higher de-
crease was observed. These results indicated that intrinsic
pathways involved in cell induced apoptosis by ROS genera-
tion mediated the anticancer effects of ZnTelm. This apoptotic
pathway triggered by mitochondrial dysfunctions has previ-
ously been determined for Zn-azilsartan and Zn-Losartan
complexes [38, 39]. Treatment with 75 μM ZnSO4 did not
alter Bax, Bcl-XL and caspase-3 protein levels in cells.
Furthermore, it has been reported that telmisartan cause cell
death by overlapping autophagy and apoptosis in adult T cell
leukemia cells [19] and in A549 cells [4]. The persistent au-
tophagy, which depletes the organelles and proteins, can lead
to a caspase-independent form of cell death and the mecha-
nism of autophagy can often be observed in cells producing
necrosis as a result. These findings suggested that necrosis,
autophagy, and apoptosis may coexist, and the relative contri-
butions of each process can guide the trajectory of cell death
[40]. In the A549 cell line, telmisartan at the same concentra-
tion of ZnTelm produced apoptosis and also necrosis and the
apoptotic proteins did not significantly increase in comparison
to those of the complex [41]. Moreover, it has been reported
that a moderate lysosomal rupture induces apoptosis, while
severe lysosomal damage produces necrosis [42]. Intact lyso-
somes are observed on fluorescence assays by the red granular
cell distribution (AO staining) upon exposition of cells to
75μMZntelm (but not with telmisartan), and this is a possible
mechanism of the apoptotic processes shown by the complex
(Fig. S6). While “mol-to-mol” comparisons between ligand,
metal, and complex are difficult to be performed for com-
pounds with a 2:1 stoichiometry, an additive effect where
the behavior of the complex is equivalent to that of the metal
plus the ligand (in a double ratio) can be ruled out. The com-
parisons of the effects of 2 mol of ligand plus 1 mol of metal
showed differences in ROS generation (antagonistic effect)
and GSH depletion (synergistic effect) and allow us to deter-
mine that the differences between the effects of the compo-
nents separately and the metal complex are significant.
Table 2 Thermodynamic parameters for the interactions of BSA with
telmisartan and ZnTelm
Compounds ΔH (KJ mol−1) ΔS (J mol−1) ΔG (KJ mol−1)
Telmisartan 23.3 45.48 − 36.85 (298 K)
− 37.4 (310 K)
ZnTelm − 43.10 − 48.12 − 28.76 (298 K)
− 28.19 (310 K)
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Moreover, the metal complex has the advantage that by sup-
plying equal concentrations of the ligand and the complex
(e.g., 50 μM), twice as much telmisartan can be incorporated
and that would eventually reduce the side effects of the drug
alone. Furthermore, the neutral coordination complex could
be a better carrier of the anionic telmisartan (deprotonated at
physiological pH values).
Conclusion
To provide other therapeutic properties to commercial drugs,
we have prepared and characterized the Zn(II) complex coor-
dinated to the antihypertensive drug telmisartan, ZnTelm. The
complex confers marked anticancer effects, which induces
oxidative stress with an intrinsic apoptotic pathway including
regulation of proteins related to apoptosis improving the anti-
proliferative action of the parent drug. In addition, the com-
plex did not affect the viability of normal fibroblasts, which
accounts for the specificity of the compound. BSA could
transport and deliver the complex and telmisartan (with low
affinity) through different mechanisms of binding. In conclu-
sion, we have shown that the ZnTelm complex designed by
structural modification of telmisartan by Zn(II) complexation
enhanced the biological properties of the antihypertensive
drug and can be evaluated for its potential as new metal-
based drug for the treatment of cancer.
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